1Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressurelowering and low-dose aspirin in patient with hypertension: principal results of the Gypertension Optimal Trea tment (HOT) randomizedtrial. Lancet, 1998, 351: 1755 - 1762.
2Wsome G, Short RL, Cushman IC, et al. The role of diastolic blood Pressure when treating isolated systolic hyoertension. Arch Int Med, 1999,159:2004.
31999 World Health Organizition-International Society of Hypertension guidelines for the Management of Hypertension Guidelines Subcommitlee. J Hypert,1999,17:151 - 183.
4Tian B,Meng QC, Chen YF, et al. Blood pressures and cardiovascular homeostasis in mice having reduced or absent angiotensin-cnverting enzyme gene function. Hypertens, 1997,30:128.
5Crozier I, Okram H, Awan N, et al. Losartan in heart failure, Hemodynamic effects and tolerabillty. Losartan in heart failure. Hemodynamic effects and tolerability. Losartan Hemodynamic Study Group. Circulation, 1995,91:691 - 697.
6Gradman AH, Arcuri KE, Goldberg AI, et al. A randomized placebo-controlled, duble-blind, parallel study of various doses of losartan potassium compared with enalapril maleate in patients with essential hypertension. Hypertensin, 1995,25: 1345 - 1350.
7Timmermans PB, Wong PC, Chiu AT, et al. Angiotensin Ⅱ receptors and angiotensin Ⅱ receptor antagonists. Pharmacov Rev, 1993,45:205 - 251.
8Timmermans PB, Benfield P, Chiu AT, et al. Angiotensin Ⅱ receptors and functional correlates. Am J Hypertens, 1992,221 S - 235 S.
9Bauer JH, Reams GP. The angiotensin Ⅱ type Ⅰ receptor antagonists. A new class of anti-hypertensive drugs. Arch Intern Med, 1995,155: 1361-1368.
10Buter H, Navis G, de Zeeuw D, et al. Renal hemodynamic effects of candesartan in normal and impaired renal function in humans. Kidney int, 1997, 52(Suppl 63):S 185-S 187.
